Comments
Suven Life Sciences has secured a product patent each from the African Regional Intellectual Property Organisation (Aripo) and South Korea corresponding to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases. The two patents are valid through 2033 and 2034, respectively, the company said in a BSE filing.
“We are pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life CEO Venkat Jasti said.
According to the company, the granted claims of the patents are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, Parkinsons and Schizophrenia. The stock was trading 1 per cent higher at Rs 226.65 apiece on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.